Literature DB >> 7623570

Risk of neoplasia in renal transplant patients.

N J London1, S M Farmery, E J Will, A M Davison, J P Lodge.   

Abstract

Renal allograft recipients are at an increased risk of neoplasia, although the extent of the problem has not been established in a typical European transplant population. To assess this risk we did a comprehensive, retrospective study of 918 patients transplanted at one centre over 24 years. The centre (Leeds) serves Yorkshire and Humberside, a region in northern England with a population of 3.6 million. The search, which made use of six sources of information, revealed 70 patients (7.6%) who had developed a neoplastic lesion, 10 patients having more than one type. More than half (42) were cutaneous lesions (mostly squamous cell carcinomas). The risk of developing neoplasia in the first 10 years after transplantation was calculated to be 14%. By 20 years this had risen to 40% compared with a 6% cumulative risk of neoplasia in an age-matched control population (p < 0.005). The full extent of this problem in the European transplant population has been underestimated and, now that recipients are surviving longer, there is a clear need for both lifelong surveillance and closer investigation of these patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623570     DOI: 10.1016/s0140-6736(95)92780-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  37 in total

1.  Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients.

Authors:  Sung Taek Park; Min Jong Song; Jong Sup Park; Soo Young Hur; Chung Won Lee
Journal:  World J Surg Oncol       Date:  2011-07-13       Impact factor: 2.754

Review 2.  Hematopoietic stem cell infusion/transplantation for induction of allograft tolerance.

Authors:  Jose M M Granados; Gilles Benichou; Tatsuo Kawai
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

3.  De novo malignancy after paediatric renal replacement therapy.

Authors:  H M Coutinho; J W Groothoff; M Offringa; M P Gruppen; H S Heymans
Journal:  Arch Dis Child       Date:  2001-12       Impact factor: 3.791

Review 4.  Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach.

Authors:  Hajime Sasaki; Tetsu Oura; Thomas R Spitzer; Yi-Bin Chen; Joren C Madsen; James Allan; David H Sachs; A B Cosimi; Tatsuo Kawai
Journal:  Hum Immunol       Date:  2017-11-22       Impact factor: 2.850

5.  T-Cell type acute lymphoblastic leukemia following cyclosporin A therapy for aplastic anemia.

Authors:  Y Hirose; Y Masaki; K Ebata; J Okada; C G Kim; N Ogawa; Y Wano; S Sugai
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

6.  Cyclosporin-A associated malignancy.

Authors:  Jonathan M Durnian; Rosalind M K Stewart; Richard Tatham; Mark Batterbury; Stephen B Kaye
Journal:  Clin Ophthalmol       Date:  2007-12

7.  Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.

Authors:  G Ponti; G Pellacani; C Ruini; A Percesepe; C Longo; V Desmond Mandel; F Crucianelli; G Gorelli; A Tomasi
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

8.  Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.

Authors:  Manikkam Suthanthiran; Minoru Hojo; Mary Maluccio; Daniel J Boffa; Fu L Luan
Journal:  Trans Am Clin Climatol Assoc       Date:  2009

9.  Lymphoproliferative disorders in Oxford renal transplant recipients.

Authors:  W D Bates; D W R Gray; M A Dada; R Chetty; K C Gatter; D R Davies; P J Morris
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

10.  Kaposi's sarcoma after liver transplantation.

Authors:  Fabrizio Di Benedetto; Stefano Di Sandro; Nicola De Ruvo; Massimiliano Berretta; Michele Masetti; Roberto Montalti; Roberto Ballarin; Stefania Cocchi; Leonardo Potenza; Mario Luppi; Giorgio E Gerunda
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-09       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.